Pharmacotherapeutic modulation of myocardial reperfusion injury aims to limit the additional damage that occurs when blood flow is restored after ischemia, such as in acute myocardial infarction. Reperfusion can trigger oxidative stress, inflammation, calcium overload, and mitochondrial dysfunction. Various drugs targeting these pathways have been investigated, but achieving consistent clinical benefit remains challenging.